How do I read and understand my Colorectal Cancer pathology report

Understanding Your Colorectal Cancer Pathology Report

A pathology report is your detailed "cancer blueprint"—it describes what the pathologist (a doctor who examines tissue under a microscope) found in your tumor sample. Let me walk you through the key sections and what they mean.

---

MAIN SECTIONS OF YOUR REPORT

1. TUMOR GRADE (How abnormal do the cancer cells look?)

What it means: Grade describes how different the cancer cells are from normal colon cells.

• Grade 1 or 2 (Low-grade): Cancer cells look fairly organized and similar to normal cells. Generally slower-growing.
• Grade 3 or 4 (High-grade): Cancer cells look very disorganized and abnormal. Generally faster-growing and more aggressive.

According to NCCN Guidelines for Colorectal Cancer, grade is one of the first prognostic factors your doctor will evaluate.

---

2. DEPTH OF INVASION (How deep did the cancer go?)

This is reported as the "T" stage (T1, T2, T3, T4):

• T1: Cancer invaded through the inner lining into the submucosa (the layer beneath)
• T2: Cancer reached the muscle layer
• T3: Cancer broke through the muscle into the fatty tissue outside the colon/rectum
• T4: Cancer reached the outer lining (peritoneum) or invaded nearby organs

Why this matters: Deeper invasion generally means higher risk of spread and may influence treatment decisions.

---

3. LYMPH NODE STATUS (Did cancer spread to lymph nodes?)

This is reported as the "N" stage:

• N0: No cancer in lymph nodes examined
• N1: Cancer found in 1-3 lymph nodes
• N2: Cancer found in 4 or more lymph nodes

Important detail: Your report should state how many lymph nodes were examined and how many contained cancer. According to NCCN Guidelines, examining at least 12 lymph nodes is important for accurate staging.

---

4. MARGINS (Did the surgeon get it all?)

Your report describes margins in several directions:

• Proximal margin: The edge toward the upper colon
• Distal margin: The edge toward the lower colon/rectum
• Radial/Circumferential margin (CRM): The outer edge of the tissue removed

What you want to see: "Negative margins" or "margins clear of tumor"

For rectal cancer specifically: The circumferential resection margin (CRM) is especially important. According to NCCN Rectal Cancer Guidelines, a positive CRM (tumor within 1mm of the edge) is a strong predictor of local recurrence and may influence whether additional radiation therapy is recommended.

---

5. LYMPHOVASCULAR INVASION (LVI)

What it means: Did the pathologist see cancer cells inside blood vessels or lymphatic vessels?

• Absent/Negative: No invasion seen (better)
• Present/Positive: Cancer cells found in vessels (concerning—suggests higher risk of spread)

This is an independent prognostic factor that your oncologist will consider.

---

6. PERINEURAL INVASION (PNI)

What it means: Did cancer cells invade the nerves in the tissue?

According to NCCN Guidelines, perineural invasion is an independent predictor of worse outcomes. For stage II rectal cancer, patients with PNI have significantly worse 5-year disease-free survival (29% vs. 82% without PNI).

• Absent: Better prognosis
• Present: May influence treatment recommendations

---

7. TUMOR BUDDING (especially important for Stage II cancers)

What it means: "Tumor buds" are single cells or small clusters (≤4 cells) at the advancing edge of the cancer.

Scoring:

• Low tier (0-4 buds): Lower risk
• Intermediate tier (5-9 buds): Intermediate risk
• High tier (10+ buds): Higher risk

According to NCCN Guidelines, high-tier tumor budding is considered an adverse (high-risk) factor in stage II colon cancer and may influence whether adjuvant (post-surgery) chemotherapy is recommended.

---

8. TUMOR DEPOSITS

What it means: These are irregular clusters of cancer cells in the fatty tissue around the colon/rectum that are not lymph nodes.

According to NCCN Guidelines, tumor deposits are associated with reduced disease-free and overall survival, and their number should be recorded in your report.

---

9. TREATMENT EFFECT (if you had chemotherapy or radiation before surgery)

If you received neoadjuvant therapy (treatment before surgery), your report should describe how much the tumor responded:

• Grade 0 (Complete response): No remaining viable cancer cells
• Grade 1 (Moderate response): Only small clusters or single cells remaining
• Grade 2 (Minimal response): Residual cancer with predominant fibrosis (scar tissue)
• Grade 3 (Poor response): Minimal tumor kill; extensive residual cancer

---

10. MOLECULAR/GENETIC TESTING (increasingly important)

Your report may include results for:

KRAS, NRAS, and BRAF mutations:

• According to NCCN Guidelines, all patients with metastatic colorectal cancer should be tested for these mutations
• Wild-type (normal) KRAS/NRAS: May be eligible for targeted antibody therapies (cetuximab or panitumumab)
• Mutated KRAS/NRAS: These mutations typically make patients ineligible for these targeted therapies
• BRAF V600E mutation: Associated with worse prognosis; requires special treatment considerations

Mismatch Repair (MMR) / Microsatellite Instability (MSI) Testing:

• Proficient MMR (pMMR) or Microsatellite Stable (MSS): Normal DNA repair
• Deficient MMR (dMMR) or MSI-High (MSI-H): Abnormal DNA repair, which may indicate Lynch syndrome and opens up immunotherapy options

According to NCCN Guidelines, universal MMR or MSI testing is recommended in all newly diagnosed patients with colorectal cancer.

HER2 and NTRK Fusions:

• Less common but important for targeted therapy eligibility if present

---

PUTTING IT TOGETHER: YOUR STAGE

Your pathology report feeds into your TNM stage (Tumor-Node-Metastasis):

• Stage I: T1-2, N0 (limited depth, no lymph node involvement)
• Stage II: T3-4, N0 (deeper invasion, but no lymph nodes involved)
• Stage III: Any T, N1-2 (lymph node involvement present)
• Stage IV: Any T, Any N, M1 (cancer spread to distant organs)

---

QUESTIONS TO ASK YOUR ONCOLOGIST

1. What is my TNM stage, and what does that mean for my prognosis?
2. Were all the margins negative, and what does that mean for my treatment?
3. Do I have any high-risk features (high grade, LVI, PNI, high tumor budding, positive CRM)?
4. What do my molecular test results show (KRAS, NRAS, BRAF, MMR/MSI status)?
5. Based on these findings, what treatment do you recommend? (surgery alone vs. chemotherapy vs. radiation)
6. What is my surveillance plan? (follow-up imaging, blood tests, colonoscopy schedule)
7. Should I consider genetic counseling (especially if MMR/MSI-H or family history)?

---

KEY TAKEAWAY

Your pathology report is the foundation for all treatment decisions. It's not just a list of findings—it's a detailed map of your cancer that helps your oncologist determine:

• Your risk of recurrence
• Whether you need additional treatment beyond surgery
• Which targeted therapies might work for you
• Your surveillance schedule

Don't hesitate to ask your doctor to explain any terms or findings you don't understand. A good oncologist will take time to walk through your report